Literature DB >> 14976596

Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis.

Arumugam Balamurugan1, Surendra K Sharma, Narinder K Mehra.   

Abstract

Although both differential susceptibility to Mycobacterium tuberculosis infection and disease pathogenesis depend on a multitude of factors, elucidation of specific host genetic markers, particularly those in the human major histocompatibility complex, is important. The present study is an attempt to delineate human leukocyte antigen (HLA) class I association in tuberculosis (TB) on the basis of a shared sequence motif in peptide-binding pockets of HLA molecules. In patients with pulmonary TB and miliary/disseminated TB, we observed significantly increased frequencies of A3-like supertypes and decreased frequencies of A1-like supertypes. These 2 positively and negatively associated supertypes (allele groups) share a similar peptide-binding motif, except for residues in pocket F of the HLA class I molecules. In addition, the HLA-Cw specificities that are major ligands for killer cell immunoglobulin-like (inhibitory) receptors (KIRs), particularly KIR2DL1 (Cw2, Cw4, and CW5) and KIR2DL2 (Cw1, Cw3, and Cw7), were found more frequently among patients with TB, which suggests a possible inhibition of natural killer cell activity against the infected target cells. The results of the present study suggest that the frequent occurrence of HLA class I specificities comprising an A3-like peptide-binding motif and the increased occurrence of ligands for KIR2DL in TB together may influence the outcome of TB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976596     DOI: 10.1086/381689

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Human leukocyte antigen class I region single-nucleotide polymorphisms are associated with leprosy susceptibility in Vietnam and India.

Authors:  Andrea Alter; Nguyen Thu Huong; Meenakshi Singh; Marianna Orlova; Nguyen Van Thuc; Kiran Katoch; Xiaojiang Gao; Vu Hong Thai; Nguyen Ngoc Ba; Mary Carrington; Laurent Abel; Narinder Mehra; Alexandre Alcaïs; Erwin Schurr
Journal:  J Infect Dis       Date:  2011-05-01       Impact factor: 5.226

Review 2.  Population structure and infectious disease risk in southern Africa.

Authors:  Caitlin Uren; Marlo Möller; Paul D van Helden; Brenna M Henn; Eileen G Hoal
Journal:  Mol Genet Genomics       Date:  2017-02-22       Impact factor: 3.291

3.  [Association between HLA-A and HLA-DRB1 allele polymorphisms and susceptibility to tuberculosis in southern Chinese population].

Authors:  Chunxin Liao; Jiahui Yang; Jinli Wang; Xialin Du; Ruining Wang; Shimeng Zhang; Wenting He; Qian Wen; Li Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

Review 4.  Ecogenomics of respiratory diseases of public health significance.

Authors:  Stavros Garantziotis; David A Schwartz
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

Review 5.  An update on granulomatous diseases of the oral tissues.

Authors:  Faizan Alawi
Journal:  Dent Clin North Am       Date:  2013-08-15

6.  Associations between human leukocyte antigen class I variants and the Mycobacterium tuberculosis subtypes causing disease.

Authors:  Muneeb Salie; Lize van der Merwe; Marlo Möller; Michelle Daya; Gian D van der Spuy; Paul D van Helden; Maureen P Martin; Xiao-Jiang Gao; Robin M Warren; Mary Carrington; Eileen G Hoal
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

7.  HLA class I supertypes: a revised and updated classification.

Authors:  John Sidney; Bjoern Peters; Nicole Frahm; Christian Brander; Alessandro Sette
Journal:  BMC Immunol       Date:  2008-01-22       Impact factor: 3.615

Review 8.  HLA-Cw1 and Psoriasis.

Authors:  Yi-Wei Huang; Tsen-Fang Tsai
Journal:  Am J Clin Dermatol       Date:  2021-01-18       Impact factor: 7.403

Review 9.  Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility.

Authors:  Murugesan Harishankar; Paramasivam Selvaraj; Ramalingam Bethunaickan
Journal:  Front Med (Lausanne)       Date:  2018-08-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.